Fig. 1 · Structure

Documents & Downloads

Clemastine fumarate

Cat. No. A10226 CAS 14976-57-9

Histamine Receptor antagonis

Clemastine is a selective histamine H1 antagonist. It binds to the histamine H1 receptor, thus blocking the action of endogenous histamine, which leads to temporary relief of the negative symptoms caused by histamine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Histamine H1 receptor 3 nM

Clemastine fumarate Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Clemastine fumarate from 3 published references. In vitro models include spinal primary microglia from SOD1-G93A mice at PND 120. In vivo models include SOD1-G93A mice.

Clemastine fumarate In Vitro Studies

Spinal primary microglia from SOD1-G93A mice were exposed to Clemastine. Treatment reduced SOD1 protein by about 50 % relative to control SOD1-G93A microglia. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Clemastine and SOD1 protein in spinal primary microglia

Cell-based study · Spinal primary microglia from SOD1-G93A mice at PND 120 [1]

Spinal primary microglia from SOD1-G93A mice were exposed to Clemastine at 30 μM for 6 h. SOD1 protein was reduced by about 50 % relative to control SOD1-G93A microglia.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SOD1 proteinSOD1 protein about 50 %[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM
Exposure duration
6 h
Method
exposed to clemastine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Clemastine

The paper names Clemastine without stating the salt or form; not verified as the fumarate form supplied as A10226. No dose conversion or lot validation.

Results > In primary spinal microglia from symptomatic SOD1-G93A mice, clemastine modulates inflammation and induces autophagy (S112, S114)

SOD1 protein: SOD1 protein; comparator: control SOD1-G93A microglia — Results > In primary spinal microglia from symptomatic SOD1-G93A mice, clemastine modulates inflammation and induces autophagy (S112)

Clemastine fumarate In Vivo Studies

In SOD1-G93A mice, intraperitoneal Clemastine significantly increased median survival in the short-treatment group, while the long-treatment group showed no significant difference from vehicle controls. In male Sprague-Dawley rats following bilateral common carotid artery ligation, intraperitoneal Clemastine reversed reduced myelin thickness compared with PBS treatment after ligation. In male APP/PS1 transgenic mice, oral Clemastine reduced cortical Aβ plaque numbers and covering area compared with chow without Clemastine. [1,2,3]

Median survival in SOD1-G93A mice

Animal study · SOD1-G93A mice [1]

Clemastine treatment up to postnatal day 120 prolongs survival in SOD1-G93A mice. When clemastine was instead administrated in SOD1-G93A mice up to the end stage (long treatment, blue line), it failed to affect disease progression and survival.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
median survivalmedian survival 186 days for clemastine vs 170 days for vehicle[1]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
five times a week by intraperitoneal injection starting from postnatal day 40 (a time that provided promising results with a lower dose of 10 mg/kg) until either the end stage or postnatal day 120.
Vehicle
30 % sulfobutylether-β-cyclodextrin (SBE)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Clemastine 50 mg/kg body weightVehicle groups received 30 % SBE.Short clemastine-treated mice show a significant difference in median survival, with respect to vehicle-treated SOD1-G93A mice (186 days for clemastine vs 170 days for vehicle; p < 0.05). Long clemastine-treated mice show no significant differences in median survival with respect to vehicle-treated SOD1-G93A mice (160 days for clemastine vs 160 days for vehicle).[1]
Clemastine 50 mg/kg body weight
Model: SOD1-G93A mice
Methods and source locations

Compound reported in the paper: Clemastine

The paper names Clemastine without stating the salt or form; not verified as the fumarate form supplied as A10226. No dose conversion or lot validation.

Methods > Pharmacological treatments with clemastine and analysis of disease progression (S14, S15); Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S58, S60, S61)

median survival: median survival; comparator: Vehicle groups received 30 % SBE. — Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S60, S61)

Clemastine 50 mg/kg body weight · Methods > Pharmacological treatments with clemastine and analysis of disease progression (S14); Results > Clemastine short treatment prolongs survival in SOD1-G93A mice (S60, S61)

Clemastine and myelin thickness after BCCAO

Animal study · male Sprague-Dawley (SD) rats; bilateral common carotid artery ligation (BCCAO) [2]

Male Sprague-Dawley rats received intraperitoneal Clemastine at 1mg/kg after bilateral common carotid artery ligation, with PBS-treated rats as controls. Clemastine reversed the reduced myelin thickness in BCCAO rats, with an averaged g-ratio of 0.7.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
axon diameter/fiber diameter of myelinated axonsg-ratio the averaged g-ratio totaled 0.7[2]

Conditions shared by the study groups

Route
intraperitoneally injected
Treatment course
after BCCAO; at 28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Clemastine 1mg/kgintraperitoneally injected with the same volume of 0.01 mol/L (M) phosphate-buffer saline (PBS) buffer after BCCAOAfter the intervention by clemastine, the averaged g-ratio totaled 0.7, indicating that clemastine reversed the reduced myelin thickness in BCCAO rats[2]
Clemastine 1mg/kg
Model: male Sprague-Dawley (SD) rats; bilateral common carotid artery ligation (BCCAO)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Clemastine

The paper names Clemastine without stating the salt or form; not verified as the fumarate form supplied as A10226. No dose conversion or lot validation.

Methods > Animals (S1, S3, S4, S5); Methods > Treatment of microglial cells culture (S26); Methods > Treatment of OPCs culture (S43); Methods > Electron microscopy (S113); Results > Ultrastructural study (S184, S187)

axon diameter/fiber diameter of myelinated axons: axon diameter/fiber diameter of myelinated axons; comparator: intraperitoneally injected with the same volume of 0.01 mol/L (M) phosphate-buffer saline (PBS) buffer after BCCAO — Results > Ultrastructural study (S184, S187)

Clemastine 1mg/kg · Methods > Animals (S4); Methods > Electron microscopy (S113); Results > Ultrastructural study (S187)

Clemastine and cortical amyloid plaques in APP/PS1 mice

Animal study · Male APP/PS1 transgenic mice; cortex; n = 4 mice per group [3]

Male APP/PS1 transgenic mice received oral Clemastine at 10 mg/kg/day, with chow without clemastine as the control. Cortical Aβ plaque numbers and covering area showed an average reduction of over 50%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
covering areas of Aβ plaquesCortical Aβ plaque covering area over a 50% reduction[3]

Conditions shared by the study groups

Route
orally administrated
Treatment course
15-month-old APP/PS1 mice for 2 months
Vehicle
standard laboratory chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Clemastine 10 mg/kg/daythe same chow without clemastineFor the cortex, on average, there was over a 50% reduction of the Aβ plaque numbers and the covering area of it[3]
Clemastine 10 mg/kg/day
Model: Male APP/PS1 transgenic mice; cortex; n = 4 mice per group
Methods and source locations

Compound reported in the paper: Clemastine

Evidence for Clemastine as the sodium form reported in the paper, not the fumarate form supplied as A10226; no salt equivalence, dose conversion or lot validation.

Materials and Methods > Animals (S2); Materials and Methods > Drug Treatments (S4, S5); Results > Chronic Treatment of Clemastine Rescues the Short-Term Memory Deficit of Aged APP/PS1 Mice (S60); Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S74, S75); FIGURE 2 legend (S120, S123)

covering areas of Aβ plaques: covering areas of Aβ plaques; comparator: the same chow without clemastine — Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S74, S75)

Clemastine 10 mg/kg/day · Materials and Methods > Drug Treatments (S4); Results > Chronic Treatment of Clemastine Rescues the Short-Term Memory Deficit of Aged APP/PS1 Mice (S60); Results > Chronic Treatment of Clemastine Ameliorates the Accumulation of Amyloid-β in the Aged APP/PS1 Mice Brain (S75)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 14976-57-9
Applications Histamine Receptor antagonis
Formula C21H26ClNO.C4H4O4
Molecular Weight 459.96
Synonyms meclastin
SMILES
C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 31 mg/mL (67.39 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Clemastine fumarate Research References

  1. [1] Apolloni S, Fabbrizio P, Amadio S, et al. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J Neuroinflammation (2016). PMID: 27549088 DOI: 10.1186/s12974-016-0658-8 Source material
  2. [2] Xie D, Ge X, Ma Y, et al. Clemastine improves hypomyelination in rats with hypoxic-ischemic brain injury by reducing microglia-derived IL-1β via P38 signaling pathway. J Neuroinflammation (2020). PMID: 32061255 DOI: 10.1186/s12974-019-1662-6 Source material
  3. [3] Xie YY, Pan TT, Xu DE, et al. Clemastine Ameliorates Myelin Deficits via Preventing Senescence of Oligodendrocytes Precursor Cells in Alzheimer's Disease Model Mouse. Front Cell Dev Biol (2021). PMID: 34746130 DOI: 10.3389/fcell.2021.733945 Source material

Added to your cart

View Cart Checkout
Loading...